NDC product
CARBIDOPA, LEVODOPA AND ENTACAPONE
NDC 16571-689 · Rising Pharma Holdings, Inc.
Key facts
| Product NDC | 16571-689 |
|---|---|
| Proprietary name | CARBIDOPA, LEVODOPA AND ENTACAPONE |
| Nonproprietary name | CARBIDOPA, LEVODOPA AND ENTACAPONE |
| Substances | CARBIDOPA, LEVODOPA, ENTACAPONE |
| Dosage form | TABLET, FILM COATED |
| Route | ORAL |
| Labeler | Rising Pharma Holdings, Inc. |
| Product type | HUMAN PRESCRIPTION DRUG |
| Marketing category | ANDA |
| Application number | ANDA213212 |
| Pharmacologic classes | Amino Acids, Aromatic [CS], Aromatic Amino Acid [EPC], Catechol O-Methyltransferase Inhibitors [MoA], Catechol-O-Methyltransferase Inhibitor [EPC] |
| Marketing start | Aug 5, 2021 |
| Listing certified through | Dec 31, 2027 |
At a glance
- 1–9 Package NDCs
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About National Drug Codes (NDC)
The National Drug Code (NDC) is the FDA's product identifier for drugs; the product NDC identifies the labeler and product, and each package adds a package code.
Source: U.S. Food and Drug Administration (FDA), National Drug Code Directory · Source date: